Hhlr Advisors, Ltd. Bei Gene, Ltd. Transaction History
Hhlr Advisors, Ltd.
- $3.87 Billion
- Q2 2024
A detailed history of Hhlr Advisors, Ltd. transactions in Bei Gene, Ltd. stock. As of the latest transaction made, Hhlr Advisors, Ltd. holds 5,176,906 shares of BGNE stock, worth $1.12 Billion. This represents 19.1% of its overall portfolio holdings.
Number of Shares
5,176,906
Previous 5,176,906
-0.0%
Holding current value
$1.12 Billion
Previous $810 Million
8.77%
% of portfolio
19.1%
Previous 17.98%
Shares
3 transactions
Others Institutions Holding BGNE
# of Institutions
215Shares Held
42MCall Options Held
106KPut Options Held
93.1K-
Baker Bros. Advisors LP New York, NY10.6MShares$2.29 Billion20.04% of portfolio
-
Capital International Investors Los Angeles, CA7.01MShares$1.52 Billion0.21% of portfolio
-
Primecap Management CO Pasadena, CA4.99MShares$1.08 Billion0.52% of portfolio
-
Baillie Gifford & CO3.68MShares$797 Million0.42% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD2.27MShares$492 Million0.04% of portfolio
About BeiGene, Ltd.
- Ticker BGNE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 103,700,000
- Market Cap $22.5B
- Description
- BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...